Table 1 Demographic and baseline clinical characteristics
From: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
|  | NVA237 50 μg (n = 550) | Placebo (n = 267) |
|---|---|---|
Mean (SD) age, years [range] | 63.8 (9.47) [40.0-91.0] | 64.0 (8.96) [42.0-85.0] |
Male gender, n (%) | 454 (82.5) | 215 (80.5) |
Ethnicity, n (%) | Â | Â |
   Caucasian | 346 (62.9) | 166 (62.2) |
   Asian | 195 (35.5) | 94 (35.2) |
   Black | 3 (0.5) | 3 (1.1) |
   Other | 6 (1.1) | 4 (1.4) |
Mean (SD) body mass index, kg/m2 | 25.8 (5.88) | 25.6 (5.60) |
Severity of COPD, n (%) | Â | Â |
   Moderate | 331 (60.2) | 166 (62.2) |
   Severe | 217 (39.5) | 99 (37.1) |
   Very severe | 2 (0.4) | 2 (0.7) |
Mean (SD) duration of COPD, years | 5.87 (5.798) | 6.49 (6.790) |
Baseline COPD exacerbation history*, n (%) | Â | Â |
   0 exacerbations | 433 (78.7) | 210 (78.7) |
   1 exacerbation | 90 (16.4) | 43 (16.1) |
   ≥ 2 exacerbations | 27 (4.9) | 14 (5.2) |
ICS use at baseline, n (%) | 301 (54.7) | 136 (50.9) |
Smoking history, n (%) | Â | Â |
   Ex-smoker | 370 (67.3) | 176 (65.9) |
   Current Smoker | 180 (32.7) | 91 (34.1) |
Mean (SD) duration of smoking, pack years Mean (SD) FEV1 (L) pre-bronchodilator Mean (SD) FEV1 (L) post-bronchodilator | 44.9 (28.08) 1.34 (0.45) 1.49 (0.46) | 44.6 (24.80) 1.28 (0.43) 1.45 (0.45) |
Mean (SD) post-bronchodilator FEV1 percentage predicted | 54.75 (13.05) | 54.33 (12.84) |
Mean (SD) post-bronchodilator FEV1 reversibility, (%) | 13.0 (14.21) | 15.05 (13.70) |
Mean (SD) post-bronchodilator FEV1/FVC, (%) | 50.15 (10.26) | 49.92 (10.22) |